Voors AA, Mulder H, Reyes E, et al. - Given the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization was decreased by vericiguat in patients with worsening HF with reduced ejection fraction and a lower limit of baseline estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m ² , researchers herein assessed the association between the efficacy of vericiguat and baseline as well as subsequent alterations in kidney function. At baseline (n = 4956) and weeks 16, 32, and 48, measurements of core laboratory serum creatinine were obtained in VICTORIA. Worsening renal function (WRF) was evaluated using a Cox model with respect to subsequent primary events. The composite endpoint of time to cardiovascular death or first HF hospitalization was the primary outcome of VICTORIA. Findings showed that vericiguat- or placebo-treated patients had similar renal function trajectories, and vericiguat-induced beneficial impacts on the primary outcome were consistent across the complete range of eGFR and regardless of WRF.